RGX-104 free Acid is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene. LXR[1]
Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity[1]. Animal Model: NOD SCID or RAG mice injected with 1×106 SKOV3 ovarian cancer cells[1].
[1]. Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18.